Endocrine Abstracts

Background: Orlistat is a lipase inhibitor used in the treatment of obesity. Recent published work has shown that orlistat may have a role in affecting the release of appetite regulating gastrointestinal derived peptides. However, the precise effect of orlistat on these hormones remains uncertain. This study aimed to evaluate the short-term effects of orlistat with a high fat meal on levels of plasma Peptide YY (PYY) and on appetite.Methods: Ethical perm...

Objective: Bariatric surgery is currently the most effective treatment for weight loss and diabetes remission. There are conflicting reports in the literature regarding the glucagon levels after RYGB surgery, likely due to cross-reactivity with oxyntomodulin and glicentin. The aim of this study was to characterize the proglucagon peptide family responses post-RYGB surgery in obese patients with type 2 diabetes using validated assays.Method: Nineteen obes...